
pmid: 32514817
The world has given an outbreak alarm in the last two decades, with different members of the coronavirus family infecting people at different times. The spread of the SARS-CoV-2 virus, which last appeared in December 2019 in China and spread rapidly to all over the world, has led the scientific world to studies on these viruses. While scientists are trying to develop vaccines or drugs against the virus, the body's immune response to the virus is emerged the biggest guide. In this review, we aimed to provide a good view on immune strategies by comparing immunological responses to SARS-CoV-2 disease among other members of the family, SARS-CoV and MERS-CoV. In the near future, it may contribute to vaccine or drug studies to be developed on immune intervention.
SARS-CoV-2, Pneumonia, Viral, COVID-19, Severe Acute Respiratory Syndrome, Betacoronavirus, Severe acute respiratory syndrome-related coronavirus, Middle East Respiratory Syndrome Coronavirus, Humans, Coronavirus Infections, Pandemics
SARS-CoV-2, Pneumonia, Viral, COVID-19, Severe Acute Respiratory Syndrome, Betacoronavirus, Severe acute respiratory syndrome-related coronavirus, Middle East Respiratory Syndrome Coronavirus, Humans, Coronavirus Infections, Pandemics
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 23 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
